An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Personalis to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
On September 13, 2022, at 1:30 p.m. Eastern Time, Personalis, Inc. (NASDAQ: PSNL) will present at the Morgan Stanley 20th Annual Global Healthcare Conference in New York, NY. As a leader in advanced cancer genomics, Personalis offers innovative solutions for precision cancer therapies and diagnostics through its Personalis NeXT Platform. The company's Clinical Laboratory is recognized for its accuracy, quality, and efficiency, complying with industry standards.
Positive
None.
Negative
None.
MENLO PARK, Calif.--(BUSINESS WIRE)--
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, 2022 at 1:30 p.m. Eastern Time in New York, NY.
About Personalis
Personalis, Inc. is a leader in advanced cancer genomics, enabling the next generation of precision cancer therapies and diagnostics. The Personalis NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers and clinicians with information on all of the approximately 20,000 human genes, together with the immune system, from a single sample. To enable cancer sequencing, Personalis'Clinical Laboratory was built with a focus on clinical accuracy, quality, big data, scale, and efficiency. The laboratory is GxP-aligned as well as Clinical Laboratory Improvement Amendments of 1988-certified and College of American Pathologists-accredited. For more information, visit the Personalis website and blog and follow Personalis on LinkedIn and Twitter.
